Overview

Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to investigate the efficacy and safety of cetuximab, docetaxel, cisplatin combination as induction therapy in locally advanced head and neck squamous cell carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Collaborator:
Clinical Research Center for Solid Tumor, Korea
Treatments:
Cetuximab
Cisplatin
Docetaxel